Elite Pharma Inc
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates through Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals segments. It owns, licenses, manufactures, and sales of generic, oral do… Read more
Elite Pharma Inc (ELTP) - Total Assets
Latest total assets as of September 2025: $117.25 Million USD
Based on the latest financial reports, Elite Pharma Inc (ELTP) holds total assets worth $117.25 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Elite Pharma Inc - Total Assets Trend (1999–2025)
This chart illustrates how Elite Pharma Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Elite Pharma Inc - Asset Composition Analysis
Current Asset Composition (March 2025)
Elite Pharma Inc's total assets of $117.25 Million consist of 59.9% current assets and 40.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.7% |
| Accounts Receivable | $29.21 Million | 30.3% |
| Inventory | $16.24 Million | 16.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $5.64 Million | 5.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1999–2025)
This chart illustrates how Elite Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Elite Pharma Inc's current assets represent 59.9% of total assets in 2025, an increase from 51.6% in 1999.
- Cash Position: Cash and equivalents constituted 11.7% of total assets in 2025, down from 48.4% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 0.0% in 1999.
- Asset Diversification: The largest asset category is accounts receivable at 30.3% of total assets.
Elite Pharma Inc Competitors by Total Assets
Key competitors of Elite Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Elite Pharma Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Elite Pharma Inc generates 0.87x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Elite Pharma Inc is currently not profitable relative to its asset base.
Elite Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.04 | 3.52 | 2.01 |
| Quick Ratio | 6.34 | 2.42 | 1.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $75.12 Million | $ 32.44 Million | $ 7.30 Million |
Elite Pharma Inc - Advanced Valuation Insights
This section examines the relationship between Elite Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.69 |
| Latest Market Cap to Assets Ratio | 2.76 |
| Asset Growth Rate (YoY) | 15.2% |
| Total Assets | $96.39 Million |
| Market Capitalization | $265.56 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Elite Pharma Inc's assets at a significant premium ( 2.76x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Elite Pharma Inc's assets grew by 15.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Elite Pharma Inc (1999–2025)
The table below shows the annual total assets of Elite Pharma Inc from 1999 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $96.39 Million | +15.22% |
| 2024-03-31 | $83.65 Million | +104.55% |
| 2023-03-31 | $40.90 Million | +16.35% |
| 2022-03-31 | $35.15 Million | +34.21% |
| 2021-03-31 | $26.19 Million | +4.94% |
| 2020-03-31 | $24.96 Million | +2.27% |
| 2019-03-31 | $24.40 Million | -20.98% |
| 2018-03-31 | $30.88 Million | -9.99% |
| 2017-03-31 | $34.31 Million | +7.63% |
| 2016-03-31 | $31.88 Million | +22.99% |
| 2015-03-31 | $25.92 Million | +6.59% |
| 2014-03-31 | $24.32 Million | +118.58% |
| 2013-03-31 | $11.13 Million | +7.89% |
| 2012-03-31 | $10.31 Million | -12.52% |
| 2011-03-31 | $11.79 Million | +11.14% |
| 2010-03-31 | $10.61 Million | -2.87% |
| 2009-03-31 | $10.92 Million | -28.67% |
| 2008-03-31 | $15.31 Million | +57.90% |
| 2007-03-31 | $9.70 Million | -38.25% |
| 2006-03-31 | $15.70 Million | +69.84% |
| 2005-03-31 | $9.25 Million | +17.72% |
| 2004-03-31 | $7.85 Million | -9.69% |
| 2003-03-31 | $8.70 Million | -31.66% |
| 2002-03-31 | $12.72 Million | +3.03% |
| 2001-03-31 | $12.35 Million | +34.79% |
| 2000-03-31 | $9.16 Million | +195.56% |
| 1999-03-31 | $3.10 Million | -- |